Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03609944 · ClinicalTrials.gov registry record · NA

SpHincterotomy for Acute Recurrent Pancreatitis

A NA study of Pancreatitis and Pancreatitis, Acute, sponsored by Oregon Health and Science University.

Completed
Registry status
NA
Development phase
181
Enrollment target
20
Study locations

NCT03609944: Completed NA study of Pancreatitis and Pancreatitis, Acute, sponsored by Oregon Health and Science University.

NCT03609944 is a NA study of Pancreatitis and Pancreatitis, Acute that has completed, run by Oregon Health and Science University. The registered enrollment target is 181 participants, below the 611-participant average among 17 other Pancreatitis trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03609944, a NA study of Pancreatitis and Pancreatitis, Acute, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
NA
Development phase
181 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine if a procedure called Endoscopic Retrograde CholangioPancreatography (ERCP) with sphincterotomy reduces the risk of pancreatitis or the number of recurrent pancreatitis episodes in patients with pancreas divisum. ERCP with sphincterotomy is a procedure where doctors used a combination of x-rays and an endoscope (a long flexible lighted tube) to find the opening of the duct where fluid drains out of the pancreas. People who have been diagnosed with pancreas divisum, have had at least two episodes of pancreatitis, and are candidates for the ERCP with sphincterotomy procedure may be eligible to participate. Participants will be will be randomly assigned to either have the ERCP with sphincterotomy procedure, or to have a "sham" procedure. Participants will have follow up visits 30 days after the procedure, 6 months after the procedure, and continuing every 6 months until a maximum follow-up period of 48 months.

Primary Outcome

To test this aim, compare the incidence of acute pancreatitis \> 30 days after treatment allocation as the primary outcome measure, using the next attack of acute pancreatitis as a time-to-event outcome.

Interventions

  • PROCEDURE EUS
  • PROCEDURE ERCP with miES

Study Locations (20)

California

  • Keck Hospital of USC - Los Angeles
  • Cedars-Sinai - Los Angeles
  • UCSF Medical Center - San Francisco

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Connecticut

  • Yale School of Medicine - New Haven

Georgia

  • Emory University Hospital - Atlanta

Illinois

  • Northwestern University - Chicago

Indiana

  • Indiana University - Indianapolis

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 181 participants
Start Date 2018-09-27
Est. Completion 2025-08-31
Phase NA

What the finished NCT03609944 record still lists

NCT03609944 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 611-participant average among 17 other Pancreatitis trials with a reported enrollment target (70% lower).

The record links to 5 conditions, with Pancreatitis appearing as the primary indexed condition, and to 2 interventions - of which EUS is the first listed.

NCT03609944 names 20 study sites across 18 states, led by California, Arkansas, Connecticut.

Frequently Asked Questions

What is clinical trial NCT03609944 about?

NCT03609944 is a clinical study titled "SpHincterotomy for Acute Recurrent Pancreatitis". The purpose of this study is to determine if a procedure called Endoscopic Retrograde CholangioPancreatography (ERCP) with sphincterotomy reduces the risk of pancreatitis or the number of recurrent pancreatitis episodes in patients with pancreas divisum. ERCP with sphincterotomy is a procedure where...

What is the current status of trial NCT03609944?

This trial is currently completed. It is a NA study. The enrollment target is 181 participants. The study started on 2018-09-27. Estimated completion is 2025-08-31.

What conditions does trial NCT03609944 study?

This clinical trial studies the following conditions: Pancreatitis, Pancreatitis, Acute, Pancreas Inflamed, Pancreas Divisum, Pancreatitis Idiopathic.

What interventions are being tested in trial NCT03609944?

The interventions under investigation include: EUS (PROCEDURE), ERCP with miES (PROCEDURE).

Who is sponsoring clinical trial NCT03609944?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03609944 being conducted?

This trial has 20 study locations across Arkansas, California, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03609944's enrollment target sits among peer trials

181 10th of 17 higher than 8 of 17 other Pancreatitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04578392 · 181 participants · NA

    MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)

  • NCT05597891 · 181 participants · NA

    Endovascular Engineering ENGULF Study

  • NCT03897998 · 182 participants · Phase 2

    Neural Correlates of Hypoalgesia Driven by Observation

  • NCT04300556 · 182 participants · Phase 1

    A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03609944, the US trial registry maintained by the National Library of Medicine. NCT03609944 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.